H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Cytokinetics to $29 from $75 and keeps a Buy rating on the shares following the negative mecarbil FDA panel vote. The analyst removed omecamtiv mecarbil projections from his valuation pending any further visibility from the FDA and any potential next steps.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics (NASDAQ:CYTK) Stock Falls; Investors Disheartened by Heart Drug Problems
- Piper Sandler maintains that AdCom vote against Cytokinetics’ OM is a positive
- Cytokinetics falls 7% to $35.50 after resumption of trading
- Cytokinetics to resume trading at 18:15ET
- Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil
